Form 4: KALA BIO CFO Sells Shares to Cover Tax Obligations from RSU Vesting

KALA BIO, Inc.'s Chief Financial Officer, Mary Reumuth, sold 2,850 shares of common stock on June 3, 2025, to satisfy tax withholding obligations related to the vesting of her restricted stock units.

Summary

• Mary Reumuth, the Chief Financial Officer of KALA BIO, Inc. (KALA), reported a sale of common stock.
• The transaction involved the disposition of 2,850 shares of KALA BIO common stock.
• The sale occurred on June 3, 2025, at a weighted average price of $3.74 per share.
• The shares were sold in multiple transactions with prices ranging from $3.52 to $4.05, inclusive.
• This sale was executed under a Rule 10b5-1 trading plan, adopted on November 9, 2020.
• The purpose of the sale was to cover tax withholding obligations associated with the vesting and settlement of restricted stock units (RSUs) granted to Ms. Reumuth on May 31, 2023.
• Following this transaction, Ms. Reumuth beneficially owns 65,731 shares of KALA BIO, Inc. common stock, which includes 40,953 unvested RSUs.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The transaction is a routine sale by an insider to cover tax obligations arising from RSU vesting, executed under a pre-arranged 10b5-1 plan. This type of transaction is not typically indicative of management's view on the company's future prospects and is a common occurrence for executives receiving equity compensation.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is a routine insider transaction disclosure, common across all industries, particularly when executives' equity compensation (like RSUs) vests, often requiring sales to cover tax liabilities. It does not provide specific insights into broader industry trends or competitive dynamics within the biotechnology sector.

Stakeholder Impact

• Shareholders: The sale represents a minor dilution of ownership, but it is a routine event for tax purposes and not indicative of a lack of confidence. The number of shares sold is relatively small compared to the total shares outstanding.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Keywords

KALA BIO, KALA, Form 4, SEC filing, insider trading, stock sale, restricted stock units, RSU vesting, tax withholding, 10b5-1 plan, Mary Reumuth, Chief Financial Officer